Pipeline Insight: Innovative Therapies

Summary

Introduction

A convergence of scientific advances has enabled the identification of molecular targets specific to cancer cells, resulting in therapies with enhanced selectivity, efficacy and reduced toxicity. Developers can rise to the clinical, regulatory and economic challenges to commercialization by improving strategic decision-making in progressing drugs through the developmental pipeline.

Scope of this report

• Review of key innovatives in development including apoptosis stimulators and inhibitors of angiogenesis, signal transduction and histone deacetylation
• Analysis of trial data and marketing factors, with sales forecasts for key technologies in late-stage clinical development
• Cancer overview including epidemiology, unmet needs, disease segmentation and how innovative therapies will shift existing treatment paradigms
• Clinical, regulatory and pharmacoeconomic challenges and strategies for commercialization

Research and analysis highlights

The cytostatic nature of many molecular-targeted treatments means that significant tumor regressions are only likely to be seen in the context of combinatorial treatment approaches alongside 'classic' cytotoxic treatments and alternate molecular-targeted treatments.The financial impact of adopting novel molecular-targeted treatments may be prohibitive to market uptake. Mitigating this, improved diagnostic and predictive analysis will facilitate predictive targeting of treatments to patient populations most likely to respond.Datamonitor believes the angiogenesis and signal transduction inhibitor classes will provide the greatest revenue potential, congruent with their combined clinical and commercial appeal. The crowded and competitive signal transduction class will result in a high degree of fragmentation and cannibalization, limiting potential revenue generation.

Key reasons to read this report

• Identify the key molecular-targeted anticancer drugs in clinical development
• Assess opportunities and risks for innovative molecular targeted treatments within the oncology market
• Adopt knowledge from this report to drive strategic planning for the development of future treatments directed against unprecedented molecular targets

Content